(P076) Postoperative Treatment Recommendations for Stage I Endometrial Cancer: A Survey of Society of Gynecologic Oncology Members

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

BT is the most common AT modality recommended by SGO members in the postoperative management of stage I EC. CT was recommended in a substantial number of scenarios and even exceeded the use of EBRT in G3 disease. Although there was generally agreement about the management of low-risk EC, there was much more variability in high-intermediate–risk patients. Further studies are needed to compare these SGO members’ recommendations with those of radiation oncologists and to determine optimal management.

Brian S. De, BA, Elena Pereira, MD, Valentin Kolev, MD, Konstantin Zakashansky, MD, Peter R. Dottino, MD, Sheryl Green, MD, Vishal Gupta, MD; Icahn School of Medicine at Mount Sinai

OBJECTIVES: To assess postoperative adjuvant therapy (AT) recommendations for International Federation of Gynecology and Obstetrics (FIGO) stage I endometrioid endometrial cancer (EC) among members of the Society of Gynecologic Oncology (SGO).

METHODS: A 19-question survey was developed, approved by our institutional review board, and emailed to SGO members. Data were collected anonymously using Internet-based survey software. Demographic questions included specialty, years in practice, practice setting, and EC patient volume. Respondents were asked questions regarding preoperative workup, surgical approach, lymph node dissection (LND), and AT based on various clinicopathologic scenarios. AT options included no further treatment or any combination of brachytherapy (BT), external beam radiotherapy (EBRT), and/or chemotherapy (CT). Here, we report the results of AT recommendations. Statistical analysis was performed using Statistical Package for the Social Sciences version 22.0 (SPSS v22.0).

RESULTS: Of the 1,399 SGO members, 320 (23%) completed the survey: 97% of respondents were gynecologic oncologists or fellows, and 2% were radiation oncologists; 49% of respondents had > 10 years of experience, 81% practiced at a university hospital or a community hospital with an academic affiliation, and 87% treated > 30 EC patients yearly. As expected, AT was chosen more frequently with greater myometrial invasion, higher tumor grade (G), and lymphovascular invasion (LVI). Respondents typically did not select any AT for stage IA, G1–2 without LVI. For stage IA, G3, +LVI disease, respondents chose BT only (55%), BT + CT (16%), BT + EBRT (7%), EBRT only (5%), CT only (5%), or no further therapy (8%); used alone or in combination, respondents most frequently selected BT (82%), followed by CT (24%) and EBRT (15%). For stage IB, G3, +LVI disease, respondents chose BT only (29%), BT + CT (27%), EBRT only (13%), BT + EBRT (10%), CT only (8%), BT + EBRT + CT (6%), EBRT + CT (5%), or no further therapy (2%); used alone or in combination, respondents most frequently selected BT (73%), followed by CT (48%) and EBRT (34%). A total of 70% of respondents considered age when planning treatment. Older patients were recommended to have AT, particularly BT, in earlier stages of disease, with similar use of CT and EBRT.

CONCLUSIONS: BT is the most common AT modality recommended by SGO members in the postoperative management of stage I EC. CT was recommended in a substantial number of scenarios and even exceeded the use of EBRT in G3 disease. Although there was generally agreement about the management of low-risk EC, there was much more variability in high-intermediate–risk patients. Further studies are needed to compare these SGO members’ recommendations with those of radiation oncologists and to determine optimal management.

Proceedings of the 97th Annual Meeting of the American Radium Society- americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
Related Content